Victory Capital Management’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.34M Buy
145,077
+90,579
+166% +$2.08M ﹤0.01% 1613
2026
Q2
$1.21M Buy
54,498
+1,518
+3% +$28.2K ﹤0.01% 1823
2026
Q1
$961K Buy
52,980
+1,496
+3% +$25.8K ﹤0.01% 1859
2025
Q4
$1.01M Buy
51,484
+1,382
+3% +$26.2K ﹤0.01% 1831
2025
Q3
$634K Sell
50,102
-16,311
-25% -$186K ﹤0.01% 1997
2025
Q2
$632K Buy
66,413
+7,002
+12% +$77.1K ﹤0.01% 2009
2025
Q1
$621K Sell
59,411
-1,937
-3% -$27.7K ﹤0.01% 1973
2024
Q4
$1.45M Buy
61,348
+30,811
+101% +$911K ﹤0.01% 1629
2024
Q3
$1.1M Buy
30,537
+11,385
+59% +$453K ﹤0.01% 1742
2024
Q2
$676K Buy
+19,152
New +$557K ﹤0.01% 1882

Other funds holding DYN

Victory Capital Management's DYN Position: Q3 2026 in Review

Victory Capital Management increased its Dyne Therapeutics (DYN) stake by 166% in Q3 2026, buying an estimated $2.08M and bringing the position to 145,077 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1613.

Victory Capital Management first reported a position in DYN in Q2 2024 and has held it in 10 quarters since. 270 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Victory Capital Management held 145,077 shares of Dyne Therapeutics worth $2.34M as of Q3 2026.
  • Victory Capital Management bought 90,579 Dyne Therapeutics shares in Q3 2026, an estimated $2.08M.
  • Dyne Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #1613 holding.
  • Victory Capital Management first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 270 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.